Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 558

1.

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.

Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ.

Lancet Oncol. 2013 Aug;14(9):853-62. doi: 10.1016/S1470-2045(13)70253-5. Epub 2013 Jul 9.

2.

Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types.

Wang H, Rosen DG, Wang H, Fuller GN, Zhang W, Liu J.

Mod Pathol. 2006 Sep;19(9):1149-56. Epub 2006 May 26.

3.

Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.

Høgdall EV, Christensen L, Høgdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK.

Oncol Rep. 2007 Nov;18(5):1051-9.

PMID:
17914554
4.

Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma.

Fujimura M, Hidaka T, Kataoka K, Yamakawa Y, Akada S, Teranishi A, Saito S.

Am J Surg Pathol. 2001 May;25(5):667-72.

PMID:
11342781
5.

Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.

McCluggage WG.

Pathology. 2011 Aug;43(5):420-32. doi: 10.1097/PAT.0b013e328348a6e7. Review.

PMID:
21716157
6.

HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up.

Geisler JP, Tammela JE, Manahan KJ, Geisler HE, Miller GA, Zhou Z, Wiemann MC.

Eur J Gynaecol Oncol. 2004;25(2):165-8.

PMID:
15032273
7.

Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.

Skírnisdóttir I, Seidal T.

Int J Gynecol Cancer. 2011 Aug;21(6):1024-31. doi: 10.1097/IGC.0b013e31821dc906.

PMID:
21792012
8.

MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.

Byrne JA, Maleki S, Hardy JR, Gloss BS, Murali R, Scurry JP, Fanayan S, Emmanuel C, Hacker NF, Sutherland RL, Defazio A, O'Brien PM.

BMC Cancer. 2010 Sep 17;10:497. doi: 10.1186/1471-2407-10-497.

9.

Five-year survival in patients with endometrioid carcinoma of the ovary versus those with serous carcinoma.

Zwart J, Geisler JP, Geisler HE.

Eur J Gynaecol Oncol. 1998;19(3):225-8.

PMID:
9641218
10.

Hormone receptors and ovarian cancer survival.

Gourley C.

Lancet Oncol. 2013 Aug;14(9):794-5. doi: 10.1016/S1470-2045(13)70323-1. Epub 2013 Jul 9. No abstract available.

PMID:
23845224
11.

Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?

Moss EL, Evans T, Pearmain P, Askew S, Singh K, Chan KK, Ganesan R, Hirschowitz L.

Int J Gynecol Cancer. 2015 Sep;25(7):1201-7. doi: 10.1097/IGC.0000000000000477.

PMID:
26035124
12.

Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study.

Köbel M, Atenafu EG, Rambau PF, Ferguson SE, Nelson GS, Ho TC, Panzarella T, McAlpine JN, Gilks CB, Clarke BA, Bernardini MQ.

Gynecol Oncol. 2016 Jun;141(3):559-63. doi: 10.1016/j.ygyno.2016.04.008. Epub 2016 Apr 16.

PMID:
27072807
13.

Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.

Matsuo K, Sheridan TB, Mabuchi S, Yoshino K, Hasegawa K, Studeman KD, Im DD, Rosenshein NB, Roman LD, Sood AK.

Gynecol Oncol. 2014 Jun;133(3):473-9. doi: 10.1016/j.ygyno.2014.03.563. Epub 2014 Mar 25.

14.

Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications.

Rambau P, Kelemen LE, Steed H, Quan ML, Ghatage P, Köbel M.

Int J Mol Sci. 2017 Feb 27;18(3). pii: E515. doi: 10.3390/ijms18030515.

16.

Folate receptor alpha as a tumor target in epithelial ovarian cancer.

Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC.

Gynecol Oncol. 2008 Mar;108(3):619-26. doi: 10.1016/j.ygyno.2007.11.020. Epub 2008 Jan 28.

17.

[Prognostic differentiation of ovarian carcinomas by immunohistochemical analysis of estrogen receptor expression].

Kieback DG, Press MF, McCamant SK, Atkinson EN, Möbus VJ, Runnebaum IB, Kreienberg R, Jones LA.

Geburtshilfe Frauenheilkd. 1995 Apr;55(4):189-94. German.

PMID:
7789706
18.

HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.

Ota T, Gilks CB, Longacre T, Leung PC, Auersperg N.

Reprod Sci. 2007 Sep;14(6):605-14.

PMID:
17959889
19.

Vascular endothelial growth factor (VEGF) and cyclooxygenase 2 (COX 2) immunostaining in ovarian cancer.

Whynott RM, Manahan P, Geisler JP.

Eur J Gynaecol Oncol. 2016;37(2):164-6.

PMID:
27172738
20.

CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.

Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC Jr, Liu J.

Int J Gynecol Cancer. 2013 Jun;23(5):815-22. doi: 10.1097/IGC.0b013e31828f7a24.

Supplemental Content

Support Center